{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:30:13Z","timestamp":1740130213875,"version":"3.37.3"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T00:00:00Z","timestamp":1693958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Science"},{"DOI":"10.13039\/501100004895","name":"Fondo Social Europeo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006253","name":"Acci\u00f3","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006253","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006301","name":"CIBER","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>HIV infection has been associated with lower rates of sustained viral response (SVR) with direct-acting antivirals (DAAs). There are few data on glecaprevir\/pibrentasvir (G\/P) in HIV\/HCV coinfection outside clinical trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The HEPAVIR-DAA cohort, which recruits HIV\/HCV-coinfected patients (NCT02057003) and the GEHEP-MONO cohort (NCT02333292), including HCV-monoinfected individuals, are two concurrent ongoing multicentre cohorts of patients receiving anti-HCV treatment. Patients starting G\/P included in those cohorts were analysed. Overall SVR (ITT), discontinuations due to adverse effects, and dropouts were evaluated and compared between both cohorts.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 644 patients who started G\/P with evaluable SVR, 132 were HIV\/HCV coinfected. Overall SVR rates were 487\/512 (95.1%) in HCV-monoinfected patients versus 126\/132 (95.5%) in HIV\/HCV-coinfected patients (P\u200a=\u200a1.000). One patient (0.8%) relapsed, and another (0.8%) discontinued treatment due to side effects. SVR to 8 or 12 weeks of treatment with G\/P was similar in HIV\/HCV-coinfected versus HCV-monoinfected patients. The main reason for not reaching SVR among HIV\/HCV-coinfected patients was premature dropout linked to active drug use.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>G\/P in HIV\/HCV coinfection was highly effective and tolerable in clinical practice. SVR to 8 or 12 weeks of treatment with G\/P was similar in HIV\/HCV-coinfected compared with HCV-monoinfected patients but active drug use is still a barrier to reach HCV microelimination.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkad278","type":"journal-article","created":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T13:31:08Z","timestamp":1694007068000},"page":"2591-2596","source":"Crossref","is-referenced-by-count":4,"title":["Response to glecaprevir\/pibrentasvir in HIV\/HCV-coinfected patients in clinical practice"],"prefix":"10.1093","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0239-8417","authenticated-orcid":false,"given":"Alejandro","family":"Gonzalez-Serna","sequence":"first","affiliation":[{"name":"Infectious Diseases and Microbiology Unit, Hospital Universitario de Valme , Avda Bellavista s\/n, 41014 Seville , Spain"},{"name":"Departamento de Fisiolog\u00eda, Facultad de Farmacia, Universidad de Sevilla , Sevilla , Spain"},{"name":"Instituto de Biomedicina de Sevilla (IBiS) , Sevilla , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC) , Madrid , Spain"},{"name":"Grupo Estudio Hepatitis V\u00edricas (GEHEP) de la SEIMC, GEHEP-001 , Sevilla , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana\u00efs","family":"Corma-Gomez","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Microbiology Unit, Hospital Universitario de Valme , Avda Bellavista s\/n, 41014 Seville , Spain"},{"name":"Instituto de Biomedicina de Sevilla (IBiS) , Sevilla , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC) , Madrid , Spain"},{"name":"Grupo Estudio Hepatitis V\u00edricas (GEHEP) de la SEIMC, GEHEP-001 , Sevilla , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Tellez","sequence":"additional","affiliation":[{"name":"Grupo Estudio Hepatitis V\u00edricas (GEHEP) de la SEIMC, GEHEP-001 , Sevilla , Spain"},{"name":"UGC Enfermedades Infecciosas, Departamento de Medicina, Universidad de C\u00e1diz, Hospital Universitario de Puerto Real , C\u00e1diz , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Corona-Mata","sequence":"additional","affiliation":[{"name":"Grupo Estudio Hepatitis V\u00edricas (GEHEP) de la SEIMC, GEHEP-001 , Sevilla , Spain"},{"name":"Infectious Diseases Unit. Maimonides Institute of Biomedical Research of C\u00f3rdoba (Instituto Maim\u00f3nides de Investigaci\u00f3n Biom\u00e9dica de C\u00f3rdoba IMIBIC), Reina Sof\u00eda University Hospital of C\u00f3rdoba, University of C\u00f3rdoba , C\u00f3rdoba , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jose","family":"Rios-Villegas","sequence":"additional","affiliation":[{"name":"Grupo Estudio Hepatitis V\u00edricas (GEHEP) de la SEIMC, GEHEP-001 , Sevilla , Spain"},{"name":"Hospital Universitario Virgen Macarena , Unidad de Enfermedades Infecciosas, Sevilla , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolores","family":"Merino","sequence":"additional","affiliation":[{"name":"Grupo Estudio Hepatitis V\u00edricas (GEHEP) de la SEIMC, GEHEP-001 , Sevilla , Spain"},{"name":"Hospital Juan Ram\u00f3n Jim\u00e9nez , Unidad de Enfermedades Infecciosas, Huelva , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Galera","sequence":"additional","affiliation":[{"name":"Grupo Estudio Hepatitis V\u00edricas (GEHEP) de la SEIMC, GEHEP-001 , Sevilla , Spain"},{"name":"Hospital Universitario Virgen de la Arrixaca , Unidad de Medicina Interna, Murcia , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio Ramon","family":"Collado-Romacho","sequence":"additional","affiliation":[{"name":"Grupo Estudio Hepatitis V\u00edricas (GEHEP) de la SEIMC, GEHEP-001 , Sevilla , Spain"},{"name":"Unidad de Enfermedades Infecciosas, Hospital Universitario Torrec\u00e1rdenas , Almer\u00eda , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"De Los Santos","sequence":"additional","affiliation":[{"name":"Grupo Estudio Hepatitis V\u00edricas (GEHEP) de la SEIMC, GEHEP-001 , Sevilla , Spain"},{"name":"CIBERINFEC, Hospital Universitario de La Princesa , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep","family":"Cucurull","sequence":"additional","affiliation":[{"name":"Grupo Estudio Hepatitis V\u00edricas (GEHEP) de la SEIMC, GEHEP-001 , Sevilla , Spain"},{"name":"Medicina Interna, Fundaci\u00f3 Salut Empord\u00e0 , Figueres , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Santos","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Microbiology Unit, Hospital Universitario de Valme , Avda Bellavista s\/n, 41014 Seville , Spain"},{"name":"Instituto de Biomedicina de Sevilla (IBiS) , Sevilla , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC) , Madrid , Spain"},{"name":"Grupo Estudio Hepatitis V\u00edricas (GEHEP) de la SEIMC, GEHEP-001 , Sevilla , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sof\u00eda","family":"Garc\u00eda-Mart\u00edn","sequence":"additional","affiliation":[{"name":"Grupo Estudio Hepatitis V\u00edricas (GEHEP) de la SEIMC, GEHEP-001 , Sevilla , Spain"},{"name":"UGC Microbiolog\u00eda, Hospital Universitario de Puerto Real , C\u00e1diz , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Rivero","sequence":"additional","affiliation":[{"name":"Grupo Estudio Hepatitis V\u00edricas (GEHEP) de la SEIMC, GEHEP-001 , Sevilla , Spain"},{"name":"Infectious Diseases Unit. Maimonides Institute of Biomedical Research of C\u00f3rdoba (Instituto Maim\u00f3nides de Investigaci\u00f3n Biom\u00e9dica de C\u00f3rdoba IMIBIC), Reina Sof\u00eda University Hospital of C\u00f3rdoba, University of C\u00f3rdoba , C\u00f3rdoba , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Miguel","family":"Real","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Microbiology Unit, Hospital Universitario de Valme , Avda Bellavista s\/n, 41014 Seville , Spain"},{"name":"Instituto de Biomedicina de Sevilla (IBiS) , Sevilla , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC) , Madrid , Spain"},{"name":"Grupo Estudio Hepatitis V\u00edricas (GEHEP) de la SEIMC, GEHEP-001 , Sevilla , Spain"},{"name":"Departamento de Especialidades Quir\u00fargicas, Bioqu\u00edmica e Inmunolog\u00eda, Facultad de Medicina, Universidad de M\u00e1laga , M\u00e1laga , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4778-790X","authenticated-orcid":false,"given":"Juan","family":"Macias","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Microbiology Unit, Hospital Universitario de Valme , Avda Bellavista s\/n, 41014 Seville , Spain"},{"name":"Instituto de Biomedicina de Sevilla (IBiS) , Sevilla , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC) , Madrid , Spain"},{"name":"Grupo Estudio Hepatitis V\u00edricas (GEHEP) de la SEIMC, GEHEP-001 , Sevilla , Spain"},{"name":"Departamento de Medicina, Universidad de Sevilla , Sevilla , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,9,6]]},"reference":[{"key":"2024010911164867300_dkad278-B1","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","article-title":"Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial","volume":"17","author":"Forns","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2024010911164867300_dkad278-B2","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/hep.29541","article-title":"Glecaprevir\/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and\/or prior treatment experience: a partially randomized phase 3 clinical trial","volume":"67","author":"Wyles","year":"2018","journal-title":"Hepatology"},{"key":"2024010911164867300_dkad278-B3","doi-asserted-by":"crossref","first-page":"e0208506","DOI":"10.1371\/journal.pone.0208506","article-title":"Safety and efficacy of glecaprevir\/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older","volume":"14","author":"Foster","year":"2019","journal-title":"PloS One"},{"key":"2024010911164867300_dkad278-B4","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jinf.2022.06.005","article-title":"High efficacy of glecaprevir\/pibrentasvir for HCV-infected individuals with active drug use","volume":"85","author":"Gonzalez-Serna","year":"2022","journal-title":"J Infect"},{"key":"2024010911164867300_dkad278-B5","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1016\/j.cgh.2020.06.044","article-title":"Eight weeks treatment with glecaprevir\/pibrentasvir is safe and efficacious in an integrated analysis of treatment-naive patients with hepatitis C virus infection","volume":"18","author":"Zuckerman","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024010911164867300_dkad278-B6","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases\u2013Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection","volume":"71","author":"Ghany","year":"2020","journal-title":"Hepatology"},{"key":"2024010911164867300_dkad278-B7","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa1702417","article-title":"Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection","volume":"378","author":"Zeuzem","year":"2018","journal-title":"N Engl J Med"},{"key":"2024010911164867300_dkad278-B8","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1007\/s12325-021-01753-3","article-title":"Safety of patients with hepatitis C virus treated with glecaprevir\/pibrentasvir from clinical trials and real-world cohorts","volume":"38","author":"Forns","year":"2021","journal-title":"Adv Ther"},{"key":"2024010911164867300_dkad278-B9","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jinf.2019.05.005","article-title":"Higher relapse rate among HIV\/HCV-coinfected patients receiving sofosbuvir\/ledipasvir for 8 vs 12 weeks","volume":"79","author":"Corma-G\u00f3mez","year":"2019","journal-title":"J Infect"},{"key":"2024010911164867300_dkad278-B10","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1017\/S0950268814000041","article-title":"Alcohol misuse and illicit drug use are associated with HCV\/HIV co-infection","volume":"142","author":"Simon","year":"2014","journal-title":"Epidemiol Infect"},{"key":"2024010911164867300_dkad278-B11","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.3109\/10826084.2015.1023451","article-title":"Continued substance use among people living with HIV\u2013hepatitis-C co-infection and receiving antiretroviral therapy","volume":"50","author":"Kalichman","year":"2015","journal-title":"Subst Use Misuse"},{"author":"AEEH, SEIMC","key":"2024010911164867300_dkad278-B12"},{"key":"2024010911164867300_dkad278-B13","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1007\/s40121-021-00455-1","article-title":"Real-world outcomes in historically underserved patients with chronic hepatitis C infection treated with glecaprevir\/pibrentasvir","volume":"10","author":"Aghemo","year":"2021","journal-title":"Infect Dis Ther"},{"key":"2024010911164867300_dkad278-B14","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jhep.2019.10.020","article-title":"Glecaprevir\/pibrentasvir for 8 weeks in treatment-na\u00efve patients with chronic HCV genotypes 1\u20136 and compensated cirrhosis: the EXPEDITION-8 trial","volume":"72","author":"Brown","year":"2020","journal-title":"J Hepatol"},{"key":"2024010911164867300_dkad278-B15","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1093\/cid\/ciy220","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in patients coinfected with hepatitis C virus and human immunodeficiency virus type 1: the EXPEDITION-2 study","volume":"67","author":"Rockstroh","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2024010911164867300_dkad278-B16","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.ijantimicag.2019.07.005","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir for chronic hepatitis C virus genotypes 1\u20136 infection: a systematic review and meta-analysis","volume":"54","author":"Wang","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2024010911164867300_dkad278-B17","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.gastrohep.2021.05.015","article-title":"Non-pharmacologic direct cost of a simplified strategy with glecaprevir\/pibrentasvir for 8 weeks in na\u00efve non-cirrhotic patients with hepatitis C implemented in clinical practice. The just SIMPLE study","volume":"45","author":"Turnes","year":"2022","journal-title":"Gastroenterol Hepatol"},{"key":"2024010911164867300_dkad278-B18","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s40121-021-00410-0","article-title":"Addressing HCV elimination barriers in Italy: healthcare resource utilization and cost impact using 8 weeks\u2019 glecaprevir\/pibrentasvir therapy","volume":"10","author":"Andreoni","year":"2021","journal-title":"Infect Dis Ther"},{"year":"2017","author":"Kosloski","key":"2024010911164867300_dkad278-B19"},{"year":"2016","author":"Oberoi","key":"2024010911164867300_dkad278-B20"},{"key":"2024010911164867300_dkad278-B21","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","author":"European Association for the Study of the Liver","year":"2018","journal-title":"J Hepatol"},{"key":"2024010911164867300_dkad278-B22","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/hiv.13039","article-title":"Incidence of recently acquired hepatitis C virus infection among HIV-infected patients in southern Spain","volume":"22","author":"Gonzalez-Serna","year":"2021","journal-title":"HIV Med"},{"key":"2024010911164867300_dkad278-B23","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/add.14128","article-title":"Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: still a concern in clinical practice?","volume":"113","author":"Christensen","year":"2018","journal-title":"Addiction"},{"key":"2024010911164867300_dkad278-B24","first-page":"685","article-title":"From care to cure: demonstrating a model of clinical patient navigation for hepatitis C care and treatment in high-need patients","volume":"64","author":"Ford","year":"2017","journal-title":"Clin Infect Dis"},{"year":"2017","author":"Ward","key":"2024010911164867300_dkad278-B25"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/10\/2591\/55243438\/dkad278.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/10\/2591\/55243438\/dkad278.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T11:17:25Z","timestamp":1704799045000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/78\/10\/2591\/7261407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,6]]},"references-count":25,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,9,6]]},"published-print":{"date-parts":[[2023,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkad278","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published-other":{"date-parts":[[2023,10]]},"published":{"date-parts":[[2023,9,6]]}}}